112 results about "Mometasone furoate" patented technology

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

Disclosed are methods of introducing a suspension or solution of a medicament, preferably mometasone furoate anhydrous, into a metered dose inhaler container, said container having a valve attached thereto, said method comprising the steps of introducing mometasone furoate anhydrous, a surfactant and a chlorofluorocarbon free propellant into a vessel that is held under pressure to form a suspension or solution, circulating said suspension or solution from the vessel through a line which includes a filling head, bringing said filling head into communication with said metered dose inhaler container through said valve of said metered dose inhaler container, introducing a quantity of such suspension or solution into the container from the filling head of the line through said valve of said metered dose inhaler container, withdrawing said filling head from said metered dose inhaler container, and sealing said metered dose inhaler container, as well as the products produced thereby having an improved particle size distribution of the active ingredients in metered dose inhalers.

The invention relates to treating chronic obstructive pulmonary disease, involving the administration by inhalation of mometasone furoate particles in daily doses where at least about 250 μg of the inhaled particles have sizes equal to or less than 6.5 μm.

The invention belongs to synthetic methods of medicines, and in particular relates to a method for synthesizing mometasone furoate. According to the method, chlorination is carried out to obtain a compound 2 while an esterification reaction is carried out between a compound 1 and furoyl chloride, and ring opening operation is carried out on the compound 2 in the presence of hydrochloric acid to generate mometasone furoate. According to the method, the defects of long process route, complex reaction system, long consumed time and the like of the original process are effectively overcome. The method provided by the invention is simple in process, mild in reaction condition, high in yield, low in cost, high in quality, and low-price and easily-available in raw and auxiliary materials, and is suitable for industrial production.

The invention relates to a topically applied composition containing povidone iodine and mometasone furoate, in particular to a topically applied pharmaceutical composition which contains the micronized mometasone furoate, the povidone iodine and one or more physiologically acceptable excipients applicable to topical application; and in the pharmaceutical composition, the content of the povidone iodine is 1%-10%, and the content of the mometasone furoate is 0.01%-0.1%.

The invention relates to an external medicinal preparation, and particularly relates to an external medicine containing mometasone furoate and a preparation method thereof. In order to achieve the purpose, the invention provides mometasone furoate cream. The mometasone furoate cream is prepared from the following raw materials in parts by weight: 0.5 to 2 parts of mometasone furoate, 75 to 150 parts of an oil phase regulator, 30 to 50 parts of a consistency regulator, 60 to 100 parts of a humectant, 80 to 120 parts of a co-emulsifier, 60 to 90 parts of a co-solvent, 1 to 3 parts of a brightening agent, 30 to 50 parts of an emulsifier, 0.3 to 1 part of a preservative and 500 to 600 parts of water. The mometasone furoate cream prepared by the preparation method disclosed by the invention hasthe advantages of reduced impurity content, increased yield, advanced process, simple method and high yield.

The invention discloses nasal in-situ gel containing mometasone furoate and an H1 receptor antagonist. The nasal in-situ gel is prepared from mometasone furoate serving as an active ingredient and/or a hydrate of mometasone furoate, one or more H1 receptor antagonists, an environmentally-sensitive hydrophilic gel material, other pharmaceutically acceptable auxiliary materials and the balance of water.

The invention provides an intranasal medicinal composition. The intranasal medicinal composition contains bilastine, mometasone furoate, and thaumatin serving as a bitterness and irritation alleviator.

The invention provides a preparation method of mometasone furoate gelatin. The mometasone furoate gelatin is prepared from the following raw materials and auxiliary materials in proportion by weight of 1.0g of mometasone furoate, 8.0-10.0g of carbomer, 4.0-6.0g of triethanolamine, 50.0g of medical ethanol, 150.0g of glycerine, and 0-1.5g of ethylparaben, and purified water is added until the totalweight is 1000g, wherein the pH value of the mometasone furoate gelatin is 5.5-6.5, and the mass ratio of the triethanolamine to the carbomer is 0.40-0.55; single unknown impurities of the mometasonefuroate gelatin do not exceed 0.2%; the total impurities are not greater than 1.0%, and the mometasone furoate gelatin is stable under the high-temperature illumination condition. Besides, radix angelicae pubescentis, herba selaginellae, Chinese arborvitae twigs and leaves, hedyotis diffusa, a pharmaceutic adjuvant, azone and rice milk, which are added, have favorable treatment effect on treatment of foot fracture.

The invention discloses a nasal nano-preparation mometasone furoate liquid crystal gel nanoparticle and a preparation method thereof. The nanoparticle consists of 0.06-0.09wt% of mometasone furoate, 30-50wt% of a liquid crystal material, 20-30wt% of phosphatidylcholine, 5-15wt% of a surfactant, 5-15wt% of a solvent and 0-40wt% of de-ionized water. The preparation method of the liquid crystal gel nanoparticle comprises the following steps: firstly, uniformly mixing all raw materials except for the solvent and the de-ionized water, and adding the solvent and promoting dispersion; and then, adding the water, and implementing further dispersion via a high shear homogenizer or ultrasonic wave, so that a finished product (the liquid crystal gel nanoparticle) is obtained. The prepared mometasonefuroate liquid crystal gel nanoparticle is small in particle size, high in encapsulation efficiency, good in medicine absorption rate, good in sustained release effect and good in therapeutic effect;and the liquid crystal gel nanoparticle is obvious curative effect on allergic rhinitis and bacterial rhinitis.

The invention relates to a pharmaceutical composition which is prepared from an active component and drug auxiliary materials and is directly acted on skin. The pharmaceutical composition is characterized in that the active component contains one of mometasone furoate and azulene sulfonic acid or salt thereof.

Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.

The invention discloses mometasone furoate cream and a preparation method thereof. The mometasone furoate cream is prepared through the technology method comprising the steps that mometasone furoate is mixed with a mixture of Tween-80 and anhydrous citric acid, and then the obtained mixture is added into an aqueous propylene glycol solution. The mometasone furoate cream has the better stability, the appropriate retention amount in the skin and the lower skin penetration amount.

The invention provides a content determination method of mometasone furoate cream, and relates to the technical field of chemical detection. The content determination method comprises the following steps: preparing a beclomethasone propionate internal standard solution; preparing a mometasone furoate reference substance solution; preparing a mometasone furoate cream test solution; and measuring the content by an internal standard method. By improving the previous detection standard and resetting the detection conditions, the problems of leading peak pattern and poor symmetry of the main peak in the existing standard content determination method are effectively solved, so that the content detection of the mometasone furoate cream is more accurate and reliable.